Esperion Nominates ESP-2001 As Preclinical Development Candidate For Primary Sclerosing Cholangitis

-2.76% Post

Esperion Therapeutics, Inc.

ESPR

2.82

2.83

-2.76%

+0.35% Post

– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases –

– ESP-2001 Has the Potential to Meaningfully Impact the Progression of PSC, a Disease with No Approved Treatments –

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.